Abstract 2289P
Background
Acute myeloid leukaemias (AML) are characterised by distinct chromatin dynamics and aberrant histone methylation regulations. The reversible nature of such epigenetic modifications has become attractive for the design of new AML therapies. Histone methylation is controlled by histone methyltransferases and demethylases, and among them, LSD1 has recently gained interest and tractability with the emergence of new LSD1 inhibitor clinical candidates. Here, we describe efforts to transcriptionally and functionally define the activity of EXS74539 (‘539) - a novel potent, selective and reversible LSD1 inhibitor - as a monotherapy or in combination with AML standard of care (SoC) at the single cell level, leveraging our expertise in the use of primary AML and healthy bone marrow samples as model systems (Kornauth et al, 2022).
Methods
Using primary human material as a disease relevant model system, combined with our proprietary deep learning enabled high content imaging and image analysis platform, we explored the capacity of ‘539 to induce AML blast differentiation and/or improve first line SoC therapy potential both in primary AML samples and in non-transformed healthy bone marrow or peripheral blood mononuclear cells. Collecting baseline and treatment condition genomics and transcriptomics, we modelled the AML specific sensitivity to ‘539.
Results
Through combining single cell omics and functional response data, we demonstrate, preclinically, the capacity of ‘539 monotherapy to induce AML cell differentiation marker expression ex vivo, and the usability of ‘539 together with SoC agents. Using healthy non-transformed bone marrow and colony formation assays, we demonstrate that an adapted drug regimen limits ‘539 thrombocytopenic potential.
Conclusions
Our preclinical data demonstrated ex vivo efficacy of ‘539 against AML blast cells and supported the combinatorial potential of ‘539 with first line clinical AML treatment strategies. Leveraging the reversibility of ‘539 allowed the design of adapted drug regimens, to preserve the safety profile of this inhibitor on non-transformed healthy cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Exscientia.
Funding
Exscientia.
Disclosure
C. Boudesco, R. Okumura, M. lautizi, N. Hieger, V. Thatikonda, M. Ssenekowitsch, T. Lin, G. Fiume, R. Sehlke, T. Winkler-Penz, A. Payne, R. Paveley: Financial Interests, Personal, Full or part-time Employment: Exscientia. G.I. Vladimer: Financial Interests, Personal, Full or part-time Employment: Exscientia; Financial Interests, Personal, Stocks or ownership: Exscientia; Financial Interests, Personal, Stocks/Shares: Exscientia.
Resources from the same session
2315P - Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
Presenter: Giulia Mazzaschi
Session: Poster session 08
2316P - Integrating comprehensive cancer genome profiling into clinical practice in an Italian referral center: Results of the first year of the fpg500 programme
Presenter: Camilla Nero
Session: Poster session 08
2317P - Mutational landscape and therapeutic implications in squamous cell carcinomas
Presenter: Laila Belcaid
Session: Poster session 08
2318P - Value of broad molecular profiling for cancer diagnosis
Presenter: Lars Volker Anton Werstein
Session: Poster session 08
2319P - CADSP: A web tool for comprehensive drug sensitivity analysis in pan-cancer
Presenter: Kexin Li
Session: Poster session 08
2320P - Detection of gene fusion-induced neoepitopes in dedifferentiated liposarcoma
Presenter: Peter Horak
Session: Poster session 08
2321TiP - TEMPLE: Thiopurine enhanced mutations for PD-1/ligand-1 efficacy: A phase Ib/II clinical trial
Presenter: Christine Federspiel Secher
Session: Poster session 08
2322TiP - SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvage-therapy matching in patients with advanced and refractory carcinoma
Presenter: Jakob Riedl
Session: Poster session 08